EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prime editing: advances and therapeutic applications

Zhihan Zhao, Peng Shang, Prarthana Mohanraju, Niels Geijsen

Trends in Biotechnology · 2023-08 · 41 (8) · 1000-1012

DOI: 10.1016/j.tibtech.2023.03.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2023-08. Verfasst von Zhihan Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW)…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, CRISPR-Associated Protein 9. Die Arbeit wurde bisher 205-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council, Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas)-mediated genome editing has revolutionized biomedical research and will likely change the therapeutic and diagnostic landscape. However, CRISPR-Cas9, which edits DNA by activating DNA double-strand break (DSB) repair pathways, is not always sufficient for gene therapy applications where precise mutation repair is required. Prime editing, the latest revolution in genome-editing technologies, can achieve any possible base substitution, insertion, or deletion without the requirement for DSBs. However, prime editing is still in its infancy, and further development is needed to improve editing efficiency and delivery strategies for therapeutic applications. We summarize latest developments in the optimization of prime editor (PE) variants with improved editing efficiency and precision. Moreover, we highlight some potential therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsCRISPR-Associated Protein 9Gene EditingDNA RepairDNA

Stichwörter der Autor:innen

CRIPSR–Casgenome editingprime editingtherapeutics

Substanzen

CRISPR-Associated Protein 9DNA

Autor:innen und Institutionen

  • Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden node, The Netherlands.
  • Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden node, The Netherlands. Electronic address: p.mohanraju@lumc.n…
  • Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden node, The Netherlands. Electronic address: n.geijsen@lumc.nl.

Förderung

  • China Scholarship Council
  • Novo Nordisk Foundation

Zitieren

APA

Zhao, Z., Shang, P., Mohanraju, P., & Geijsen, N. (2023). Prime editing: advances and therapeutic applications. Trends in Biotechnology, 41(8), 1000-1012. https://doi.org/10.1016/j.tibtech.2023.03.004

Vancouver

Zhao Z, Shang P, Mohanraju P, Geijsen N. Prime editing: advances and therapeutic applications. Trends in Biotechnology. 2023;41(8):1000-1012. doi:10.1016/j.tibtech.2023.03.004

BibTeX
@article{Zhao2023,
  author = {Zhao, Zhihan and Shang, Peng and Mohanraju, Prarthana and Geijsen, Niels},
  title = {Prime editing: advances and therapeutic applications},
  journal = {Trends in Biotechnology},
  year = {2023},
  volume = {41},
  number = {8},
  pages = {1000--1012},
  doi = {10.1016/j.tibtech.2023.03.004}
}
Kostenlos starten →